(4502) –
-
Form SD TAKEDA PHARMACEUTICAL
-
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
-
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
-
Form 6-K TAKEDA PHARMACEUTICAL For: Apr 19
-
Takeda (TAK) U.S. FDA Approves Subcutaneous Administration of ENTYVIO
-
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
-
Form 6-K TAKEDA PHARMACEUTICAL For: Apr 15
-
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
-
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
-
Form 6-K TAKEDA PHARMACEUTICAL For: Mar 27
-
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
-
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
-
Takeda (TAK) Announces U.S. FDA Approval of sNDA for ICLUSIG in Adult Patients with Newly Diagnosed Ph+ ALL
-
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
-
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
-
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
-
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
-
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
-
Form 6-K TAKEDA PHARMACEUTICAL For: Feb 09
-
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
-
Form SC 13G/A TAKEDA PHARMACEUTICAL Filed by: BlackRock Inc.
-
Form SC 13G/A TAKEDA PHARMACEUTICAL Filed by: Sumitomo Mitsui Trust Holdings, Inc.
-
Form 6-K TAKEDA PHARMACEUTICAL For: Feb 02
-
Form 6-K TAKEDA PHARMACEUTICAL For: Feb 01
-
Form 6-K TAKEDA PHARMACEUTICAL For: Feb 01
-
Takeda Announces Chief Financial Officer Succession
-
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
-
Takeda’s (TAK) GAMMAGARD LIQUID Approved by U.S. FDA for Adults with CIDP
-
Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation
-
Takeda Named Global Top Employer for Seventh Consecutive Year
-
U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
Form 6-K TAKEDA PHARMACEUTICAL For: Jan 16
-
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
-
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
Form 6-K TAKEDA PHARMACEUTICAL For: Dec 14
-
Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
-
Form 6-K TAKEDA PHARMACEUTICAL For: Nov 30
-
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
-
Form 6-K TAKEDA PHARMACEUTICAL For: Nov 13
-
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic P
-
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
-
Takeda (TAK) Announces Late-Breaking Data from Phase 2b Study of TAK-279
-
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology
-
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 30
-
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 26
-
Form 6-K TAKEDA PHARMACEUTICAL For: Oct 26
-
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
-
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
Back to 4502 Stock Lookup
